Pear Therapeutics, Inc. Warrant
PEARW
PEARW was delisted on the 18th of April, 2023.
36 hedge funds and large institutions have $3.67M invested in Pear Therapeutics, Inc. Warrant in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 7 closing their positions.
10% less funds holding
Funds holding: 40 → 36 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
67% less capital invested
Capital invested by funds: $11.2M → $3.67M (-$7.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$306K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$6.57K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.79K |
| 4 |
DCM
Difesa Capital Management
New York
|
+$709 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$558 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
-$378K |
| 2 |
KCM
Kingstown Capital Management
New York
|
-$158K |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$63K |
| 4 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$53K |
| 5 |
KC
Kepos Capital
New York
|
-$40.7K |
PEARW Hedge Fund Activity: Q2 2022 in Review
36 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q2 2022, worth a combined $3.67M — down 67% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PEARW and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was LMR Partners, adding an estimated $306K. The largest seller was P. Schoenfeld Asset Management (PSAM), exiting entirely with an estimated $378K sold.
- 36 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q2 2022, down from 40 in Q1 2022.
- Funds reported $3.67M of Pear Therapeutics, Inc. Warrant stock for Q2 2022, down 67% quarter-over-quarter.
- 3 funds opened new Pear Therapeutics, Inc. Warrant positions in Q2 2022 and 7 closed out, a net change of -4 holders.
- The largest Pear Therapeutics, Inc. Warrant buyer in Q2 2022 was LMR Partners, an estimated $306K added.
- The largest Pear Therapeutics, Inc. Warrant seller in Q2 2022 was P. Schoenfeld Asset Management (PSAM), an estimated $378K sold.
Based on aggregated 13F filings for Q2 2022.